IDP-118 Vehicle Lotion

DRUG5 trials

Sponsors

Bausch Health Americas, Inc.

Conditions

Plaque PsoriasisPsoriasis

Phase 2

Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis

CompletedNCT02045277

Bausch Health Americas, Inc.Plaque Psoriasis

Start: 2014-02-28End: 2014-11-30Updated: 2020-08-20

Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis

CompletedNCT02785159

Bausch Health Americas, Inc.Psoriasis

Start: 2016-02-29End: 2016-12-31Updated: 2020-08-20

Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis

CompletedNCT02785172

Bausch Health Americas, Inc.Psoriasis

Start: 2016-04-30End: 2017-01-31Updated: 2020-08-20

Phase 3

Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis

CompletedNCT02462122

Bausch Health Americas, Inc.Plaque Psoriasis

Start: 2015-08-19End: 2016-11-14Updated: 2020-08-20

Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis

CompletedNCT02462070

Bausch Health Americas, Inc.Plaque Psoriasis

Start: 2015-08-11End: 2016-12-01Updated: 2020-08-20

Related Papers

Fixed-Combination Halobetasol Propionate/Tazarotene Lotion for Psoriasis in Patients With 3%-5% Affected Body Surface Area.

2021-08-011 citations

Fixed-Combination Halobetasol Propionate and Tazarotene Lotion for Psoriasis in Patients With Skin of Color.

2021-07-014 citations

Posttreatment maintenance of therapeutic effect with fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion for moderate-to-severe plaque psoriasis.

2021-06-163 citations

Successful Management of a Black Male With Psoriasis and Dyspigmentation Treated With Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion: Case Report

Journal of Drugs in Dermatology2020-09-014 citations